<DOC>
	<DOCNO>NCT02598310</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety nab-PTX trastuzumab ER negative HER2 positive operable ( tumor size 3cm less N0 ) breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Nab-PTX Trastuzumab ER Negative HER2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically confirm invasive breast cancer 2 . Tumor size 3cm less N0 3 . Hormone receptor identify negative 4 . HER2 positive confirm IHC 3+ FISH+ 5 . LVEF &gt; 50 % echocardiogram MUGA 6 . Adequate EKG 7 . No prior treatment breast cancer 8 . PS 01 9 . Required baseline laboratory data WBC &gt; 4,000/mm3 Neut &gt; 2,000/mm3 PLT &gt; 100,000/mm3 Hb &gt; 9.0g/dl AST ALT &lt; ULNx2.5 TBil &lt; 1.5mg/dl Serum creatinin &lt; 1.5mg/dl 10 . Written inform consent 1 . With history hypersensitivity reaction important drug study 2 . With history invasive breast cancer 3 . Bilateral invasive breast cancer 4 . Patients medical condition render intolerant primary chemotherapy relate treatment , include infection , diarrhea , intestinal paralysis , severe Diabetes Mellitus 5 . Positive HBs antigen HCV antibody 6 . With history congestive heart failure , uncontrolled symptomatic angina pectoris , arrhythmia myocardial infarction , poorly control hypertension 7 . With severe edema 8 . With severe peripheral neuropathy 9 . With severe psychiatric disorder 10 . Pregnant nursing woman 11 . The case judge unsuitable study physician</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>